Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.54 |
| ▸ | GHSR | Q92847 | 2/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22753494 | 0.92 | DPP3 (0.51) | DPP3GHSRCAPN1CTSBBCHE | |
| SCHEMBL13018973 | 0.86 | DPP3 (0.55) | DPP3CAPN1CTSB | |
| SCHEMBL13950953 | 0.86 | DPP3 (0.55) | DPP3CAPN1CTSB | |
| SCHEMBL21955442 | 0.83 | DPP3 (0.47) | DPP3 | |
| SCHEMBL10036414 | 0.82 | DPP3 (0.58) | DPP3CAPN1CTSBTACR1 | |
| SCHEMBL30051571 | 0.81 | DPP3 (0.57) | DPP3CAPN1CTSBBCHE | |
| SCHEMBL10036420 | 0.81 | DPP3 (0.48) | DPP3GHSRCAPN1CTSBTACR1 | |
| SCHEMBL30310982 | 0.81 | CCKBR (0.61) | DPP3GHSRBCHE | |
| SCHEMBL13390885 | 0.81 | DPP3 (0.49) | DPP3 | |
| SCHEMBL31238561 | 0.80 | TACR1 (0.57) | DPP3CAPN1CTSBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | DPP3 83/4885GHSR 692/4885CAPN1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.